Single-layer oral dose of neuro-attenuating ketamine
US11554100B2 · kind B2 · utility
0Cited by
6References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 6, 2020 |
| Grant date | Jan 17, 2023 |
| Priority date | — |
| Expiry date | May 6, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.